Vimarsana
Biggest News Aggregation in the World

Page 13 - James Connell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from James Connell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In James Connell Today - Breaking & Trending Today

EnginZyme raises €21 million in Series B to accelerate the commercialisation of its cell-free biomanufacturing technolog - Vimarsana News

EnginZyme raises €21 million in Series B to accelerate the commercialisation of its cell-free biomanufacturing technolog

STOCKHOLM, Dec. 19, 2022 /PRNewswire/ -- EnginZyme, a green tech company developing biomanufacturing...

Ralph's Corner Bar exhibit honors beloved Moorhead bar - Vimarsana News

Ralph's Corner Bar exhibit honors beloved Moorhead bar

MOORHEAD, Minn. (KFGO/KVRR) - The Historical and Cultural Society of Clay County announces a new exhibit remembering Ralph's Corner Bar, a popular soc...

Source: y94.com
AFYREN NEOXY Signs Deal With Excellentia for Distribution in Key North American Flavors and Fragrances Market - Vimarsana News

AFYREN NEOXY Signs Deal With Excellentia for Distribution in Key North American Flavors and Fragrances Market

Excellentia will distribute the FLAVYREN line to the major North American players in the flavors and fragrances market The deal covers the full suite of FLAVYREN natural organic acids produced

Trial for Clement Swaby, alleged campus rapist, opens with Lehigh University graduate's account of 2020 attack - Vimarsana News

Trial for Clement Swaby, alleged campus rapist, opens with Lehigh University graduate's account of 2020 attack

Clement Swaby’s trial began Tuesday with the woman he is accused of raping at an off-campus Lehigh University apartment relating the events of May 19, 2020.

Source: mcall.com
One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It - Vimarsana News

One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It

Observational study data suggest thiazolidinediones may be protective when it comes to dementia risk in patients with type 2 diabetes, whereas sulfonylureas increase the risk, compared with metformin.